CC-115: Phase I data

Top-line data from 82 evaluable patients with relapsed or refractory advanced solid tumors and hematological malignancies in a 2-part, open-label, international Phase Ia/Ib trial

Read the full 248 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE